Get the Stockscreener App
4.00
1.23%
-0.05
Lifecore Biomedical Inc stock is traded at $4.00, with a volume of 446.51K.
It is down -1.23% in the last 24 hours and down -44.60% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
See More
Previous Close:
$4.05
Open:
$4
24h Volume:
446.51K
Relative Volume:
1.93
Market Cap:
$149.91M
Revenue:
$128.45M
Net Income/Loss:
$6.54M
P/E Ratio:
80.00
EPS:
0.05
Net Cash Flow:
$-8.79M
1W Performance:
-8.26%
1M Performance:
-44.60%
6M Performance:
-43.30%
1Y Performance:
-39.39%
1-Day Range:
$3.91
$4.09
1-Week Range:
$3.87
$4.50
52-Week Range:
$3.87
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.00 | 149.91M | 128.45M | 6.54M | -8.79M | 0.05 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Sep-04-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| May-21-25 | Initiated | William Blair | Outperform |
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
View All
Lifecore Biomedical Inc Stock (LFCR) Latest News
LFCR: Barrington Research Maintains Outperform Rating with $5.50 Price Target | LFCR Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect - ACCESS Newswire
Lifecore Biomedical signs third site transfer deal in five months By Investing.com - Investing.com Australia
Lifecore Biomedical Signs Commercial Manufacturing Services Agreement with Medical Aesthetics Company - marketscreener.com
Lifecore Biomedical signs third site transfer deal in five months - Investing.com
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company - Yahoo Finance
Published on: 2026-03-23 12:54:24 - baoquankhu1.vn
Lifecore stock sinks as delayed launches push growth further out - MSN
2026-03-22 | Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation | NDAQ:LFCR | Press Release - Stockhouse
Aug Summary: Is Lifecore Biomedical Inc a strong candidate for buy and holdEarnings Overview Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Rally Mode: Is Lifecore Biomedical Inc a top pick in the sector2026 Analyst Calls & High Accuracy Investment Signals - baoquankhu1.vn
Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore Biomedical at KeyBanc Forum: Strategic Transformation Insights By Investing.com - Investing.com Canada
Lifecore Biomedical at KeyBanc Forum: Strategic Transformation Insights - Investing.com
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Lifecore Biomedical (NASDAQ:LFCR) Upgraded to Outperform at Barrington Research - MarketBeat
Why Is Lifecore Stock Sinking Tuesday?Lifecore Biomedical (NASDAQ:LFCR) - Benzinga
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Craig-Hallum Sticks to Its Buy Rating for Lifecore Biomedical (LFCR) - The Globe and Mail
Lifecore Stock Sinks As Delayed Launches Push Growth Further Out - Sahm
Green Dot Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives - simplywall.st
Lifecore Biomedical earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Lifecore Biomedical Shareholders Are Encouraged to Reach - GlobeNewswire
Lifecore Biomedical Targets 12% Revenue CAGR and 25%+ EBITDA Margin by 2029 with CDMO Growth Strategy - Minichart
Lifecore Biomedical, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-03-16 - Seeking Alpha
Rate Cut: What is the implied volatility of Lifecore Biomedical Inc2026 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn
Lifecore Biomedical Transition period Earnings Call Transcript - MarketBeat
Lifecore Biomedical Expands CDMO Capabilities with New Aseptic Filler and Strategic Growth Initiatives - Minichart
Lifecore Biomedical, Inc. Reports Earnings Results for the Fourth Quarter and Seven Months Ended December 31, 2025 - marketscreener.com
Lifecore Biomedical Q4 Earnings Call Highlights - MarketBeat
Lifecore Biomedical’s Competitive Edge in Specialized Sterile Injectables Strengthens Pricing Leverage as Recovery Reduces EBITDA Deficit - Bitget
Lifecore Biomedical reports financial results for the fourth quarter and transition period ended December 31, 2025, and provides corporate update - marketscreener.com
LFCR: Transition period saw 20% revenue growth and improved margins; strong mid-term outlook - TradingView
Lifecore Biomedical Reports Financial Results For The Fourth Quarter And Transition Period Ended December 31, 2025, And Provides Corporate Update - TradingView
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update - The Manila Times
Lifecore Biomedical: Q4 Earnings Snapshot - marketscreener.com
Lifecore (NASDAQ: LFCR) lifts margins but guides 2026 revenue below 2025 - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
LFCR Earnings History & Surprises | EPS & Revenue Results | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore Biomedical (NASDAQ:LFCR) Stock Price Down 2.9%Here's Why - MarketBeat
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum - The Manila Times
Stream Lifecore Biomedical’s KeyBanc healthcare fireside chat on Mar. 17 - Stock Titan
Lifecore Biomedical, Inc. to Announce Q4 and Transition Period Financial Results on March 16, 2026 - Quiver Quantitative
Lifecore Biomedical to Report Financial Results for the - GlobeNewswire
Lifecore to post Q4 and transition-period earnings on March 16 - Stock Titan
Ideas Watch: Is Lifecore Biomedical Inc forming bullish engulfing patternsLayoff News & AI Driven Stock Price Forecasts - baoquankhu1.vn
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment - Sahm
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):